World Fibromyalgia Awareness Day 2026 raises awareness of fibromyalgia, a chronic condition that affects millions of people and is still often misunderstood, underrecognized or difficult to diagnose.
Observed every year on May 12, the day is also noted alongside myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) and other chronic, complex illnesses, helping bring visibility to conditions that can profoundly affect daily life but may not always be outwardly visible.
May 12 was chosen to honor the birthday of Florence Nightingale, the founder of modern nursing, who is believed to have lived with a chronic illness resembling fibromyalgia or ME/CFS. Since 1992, the date has been observed internationally to raise awareness of fibromyalgia. The date also coincides with International Nurses Day, which commemorates Nightingale’s birthday.
Fibromyalgia is a long-term disorder marked by widespread pain, fatigue, sleep problems and cognitive symptoms often described as “fibro fog.” People with fibromyalgia may experience heightened pain sensitivity, meaning the nervous system processes pain signals differently.
The condition is not considered an inflammatory or autoimmune disease, but research suggests changes in the nervous system and pain-processing pathways play an important role.
In the US, fibromyalgia affects millions of people, according to the CDC. It can occur at any age, including in children, but is most common in adults and is diagnosed more often in women than in men. Individuals aged 30 to 50 and people with lupus, rheumatoid arthritis or osteoarthritis are at a greater risk of developing the condition, along with people with a family history of fibromyalgia.
Because symptoms often overlap with other conditions, patients may go through long diagnostic journeys before receiving an explanation for what they are experiencing.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Diagnosis has also evolved. Fibromyalgia was once strongly associated with “tender point” exams, but newer criteria place more emphasis on widespread pain, symptom severity, fatigue, unrefreshing sleep and cognitive symptoms that persist for at least three months.
There is currently no cure for fibromyalgia, but symptoms can be managed through a combination of approaches. Treatment may include medications, physical activity tailored to a patient’s abilities, sleep management, stress reduction, cognitive behavioral therapy and multidisciplinary care involving primary care providers, rheumatologists, pain specialists, mental health professionals and rehabilitation experts.
World Fibromyalgia Awareness Day 2026 is therefore not only about recognizing a disease; it is also about validating patient experiences, encouraging earlier diagnosis and supporting research into better treatments.
For patients living with fibromyalgia, increased awareness can help reduce stigma and improve understanding among clinicians, employers, families and the broader public.
As research continues to uncover the biological mechanisms behind chronic pain and central sensitization, fibromyalgia remains an important reminder that invisible illnesses deserve visible attention.
Recent Advances in Fibromyalgia Treatments
The treatment landscape has also seen renewed attention. In August 2025, the FDA approved Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for adults with fibromyalgia, making it the first new FDA-approved therapy for the condition in more than 15 years. The drug is a first-in-class, non-opioid, sublingual tablet of cyclobenzaprine, designed for rapid absorption, indicated for the management of fibromyalgia in adults. Taken daily at bedtime, it treats symptoms like chronic widespread pain, fatigue and poor sleep quality.
The approval added to a limited group of prescription treatment options for fibromyalgia, which has historically included drugs such as Pfizer/Viatris’ Lyrica (pregabalin), Eli Lilly’s Cymbalta (duloxetine) and Savella (milnacipran), which was previously marketed by Forest Laboratories/Allergan (now AbbVie) and developed with Cypress Bioscience.
The fibromyalgia pipeline remains relatively small, but there are a few notable programs. Axsome Therapeutics is developing AXS-14 (esreboxetine), an oral, selective norepinephrine reuptake inhibitor, for fibromyalgia.
Axsome says the drug has shown positive results in prior Phase II and Phase III testing and is in preparation for an NDA, while the company also began dosing patients in the FORWARD Phase III trial in January 2026. That study is using a randomized-withdrawal design, where responders after open-label treatment continue AXS-14 or switch to placebo to measure durability of response.
Another notable program is IMC-1, a fixed-dose combination of famciclovir and celecoxib that was originally advanced by Virios/Dogwood Therapeutics and is now tied to PRIDCor Therapeutics through a 2026 development and commercialization partnership.
IMC-1 is based on the hypothesis that herpesvirus reactivation may contribute to symptoms in some patients with fibromyalgia. Earlier data showed improvements in several fibromyalgia measures, but the larger FORTRESS Phase IIb trial did not meet its primary pain endpoint overall. The company has pointed to post-hoc findings in less treatment-experienced patients as a rationale for further development, and the asset has been described as Phase III-ready.
Fibromyalgia highlights both the scientific and commercial challenges of developing therapies for chronic pain conditions. Clinical endpoints can be complex, symptoms vary widely between patients and the condition intersects with sleep, mood, cognition and physical function. At the same time, the need for non-opioid pain treatments and more personalized approaches to chronic pain management continues to grow.
Join or login to leave a comment
JOIN LOGIN